Literature DB >> 17240838

[Screening tests and diagnostic examinations of hypertensives for primary aldosteronism].

Masao Omura1, Tetsuo Nishikawa.   

Abstract

Primary aldosteronism (PA) is a form of surgically curable secondary hypertension. The prevalence of PA among hypertensive patients is reportedly between 5 and 15% and hypokalemia is rare in patients with PA. Therefore, hypertensives should be screened for PA. The aldosterone (PAC)-renin activity (PRA) ratio (ARR) has widely been used as the initial screening for PA; however, it is reported that the diagnosis of PA should not be based on the finding of a raised ARR. We compared the sensitivity and specificity of ARR for PA screening with those of PAC and PRA in 236 hypertensives, and ROC analysis revealed that PAC and PRA are more sensitive and specific than ARR for PA screening. The sensitivity and specificity of the captopril suppression test, furosemide plus upright test and ACTH stimulation test for secondary screening for PA were retrospectively examined in 94 patients with PA and 44 patients without PA. ROC analysis demonstrated that the ACTH stimulation test was the most sensitive and specific among these three tests. Therefore, we propose that hypertensives should initially be screened for PA using the criteria of PAC > or = 12.0 ng/dl and PRA < or = 1.0 ng/ml/h and should be secondarily screened using the ACTH stimulation test. Then ACTH-stimulated adrenal venous sampling should be performed in patients with the ratio of maximal PAC to cortisol after ACTH stimulation 0.85. Patients with unilateral secretion of aldosterone2 1400 ng/dl should undergo unilateral adrenalectomy and patients with bilateral secretion of aldosterone2 1400 ng/dl should be treated with antihypertensive agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17240838

Source DB:  PubMed          Journal:  Rinsho Byori        ISSN: 0047-1860


  6 in total

1.  Primary aldosteronism in patients with acute stroke: prevalence and diagnosis during initial hospitalization.

Authors:  Yosuke Miyaji; Yuichi Kawabata; Hideto Joki; Shunsuke Seki; Kentaro Mori; Tomoya Kamide; Akira Tamase; Hiroshi Shima; Motohiro Nomura; Yoshihisa Kitamura; Hirotatsu Nakaguchi; Taichi Minami; Tetsuji Tsunoda; Mayuko Sasaki; Masayo Yamada; Fumiaki Tanaka
Journal:  BMC Neurol       Date:  2016-09-17       Impact factor: 2.474

2.  Impact of primary aldosteronism on renal function in patients with type 2 diabetes.

Authors:  Sho Katsuragawa; Yuya Tsurutani; Tomoko Takiguchi; Jun Saito; Tetsuo Nishikawa
Journal:  J Diabetes Investig       Date:  2020-07-26       Impact factor: 4.232

3.  Coexistence of Renin-independent Aldosterone Secretion and Multiple Endocrine Neoplasia Type 1 Within a Family.

Authors:  Yoshinari Obata; Kana Takayama; Yumiko Maruo; Hiroki Yamaguchi; Kohei Fujii; Sonyun Hata; Yuri Togawa; Azusa Sanda; Motohiro Kosugi; Yoji Hazama; Tetsuyuki Yasuda
Journal:  J Endocr Soc       Date:  2022-01-29

4.  Evaluation of the (1-24) adrenocorticotropin stimulation test for the diagnosis of primary aldosteronism.

Authors:  Ken Terui; Kazunori Kageyama; Takeshi Nigawara; Takako Moriyama; Satoru Sakihara; Shinobu Takayasu; Yuko Tsushima; Yutaka Watanki; Satoshi Yamagata; Aya Sugiyama; Shingo Murasawa; Yuki Nakada; Toshihiro Suda; Makoto Daimon
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-03-23       Impact factor: 1.636

5.  Evaluation of various confirmatory tests for the diagnosis of aldosterone-producing adenoma.

Authors:  Satoshi Kidoguchi; Naoki Sugano; Ruri Kawauchi; Daisuke Nakashima; Naomi Hayashi-Ishikawa; Goro Tokudome; Takashi Yokoo
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Apr-Jun       Impact factor: 1.636

6.  Primary Aldosteronism Associated with Multiple Adrenocortical Micronodules in a Patient with Renal Cell Carcinoma.

Authors:  Kazuhito Oba; Yuko Chiba; Yoko Matsuda; Takeshi Kumakawa; Rie Aoyama; Miho Akahoshi; Seiji Hashimoto; Aya Tachibana; Koichi Toyoshima; Remi Kodera; Kenji Toyoshima; Yoshiaki Tamura; Takashi Nagata; Yuto Yamazaki; Hironobu Sasano; Atsushi Araki
Journal:  Case Rep Endocrinol       Date:  2020-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.